The content on this site is intended for healthcare professionals only
Emergence of ipilimumab and vemurafenib for melanoma
The P-Medicine project; data sharing and integration for personalised medicine
Role of vemurafenib in melanoma treatment
The changing landscape of melanoma therapies: indications of better patient outcome
Combining oral targeted therapies shows early anti-tumour activity for advanced melanoma
Cancer prevention through education
New melanoma drug gives 63 percent reduction in risk of death compared to dacarbazine
Ipilimumab improves survival in metastatic melanoma
Highlights from 2011 and ASCO’s future
ASCO 2011 highlights
The future of medicine: personalised
Reducing global cancer mortality
